These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25446081)

  • 21. Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelial-mesenchymal transition.
    Zhou YC; Liu JY; Li J; Zhang J; Xu YQ; Zhang HW; Qiu LB; Ding GR; Su XM; Mei-Shi ; Guo GZ
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1530-7. PubMed ID: 22115555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells.
    Price RS; Cavazos DA; De Angel RE; Hursting SD; deGraffenried LA
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):135-43. PubMed ID: 22333686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The malignancy of liver cancer cells is increased by IL-4/ERK/AKT signaling axis activity triggered by irradiated endothelial cells.
    Kim SD; Baik JS; Lee JH; Mun SW; Yi JM; Park MT
    J Radiat Res; 2020 May; 61(3):376-387. PubMed ID: 32100006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
    Wang C; Wang L; Su B; Lu N; Song J; Yang X; Fu W; Tan W; Han B
    Prostate; 2014 May; 74(7):689-701. PubMed ID: 24619958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Radiosensitizing Potentials of Silymarin/Silibinin in Cancer: A Systematic Review.
    Gupta J; Jalil AT; Riyad Muedii ZA; Aminov Z; Alsaikhan F; Ramírez-Coronel AA; Ramaiah P; Farhood B
    Curr Med Chem; 2024; 31(42):6992-7014. PubMed ID: 37921180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells.
    Jiang C; Agarwal R; Lü J
    Biochem Biophys Res Commun; 2000 Sep; 276(1):371-8. PubMed ID: 11006131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
    Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Culture supernatants of breast cancer cell line MDA-MB-231 treated with parthenolide inhibit the proliferation, migration, and lumen formation capacity of human umbilical vein endothelial cells.
    Li CJ; Guo SF; Shi TM
    Chin Med J (Engl); 2012 Jun; 125(12):2195-9. PubMed ID: 22884152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
    Chang HR; Chen PN; Yang SF; Sun YS; Wu SW; Hung TW; Lian JD; Chu SC; Hsieh YS
    Mol Carcinog; 2011 Oct; 50(10):811-23. PubMed ID: 21574189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urotensin-II-stimulated expression of pro-angiogenic factors in human vascular endothelial cells.
    Albertin G; Guidolin D; Sorato E; Oselladore B; Tortorella C; Ribatti D
    Regul Pept; 2011 Dec; 172(1-3):16-22. PubMed ID: 21871928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF β2.
    Ting HJ; Deep G; Jain AK; Cimic A; Sirintrapun J; Romero LM; Cramer SD; Agarwal C; Agarwal R
    Mol Carcinog; 2015 Sep; 54(9):730-41. PubMed ID: 24615813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.
    Kaliberov SA; Kaliberova LN; Buchsbaum DJ
    Gene Ther; 2005 Mar; 12(5):407-17. PubMed ID: 15616600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells.
    Kim S; Choi JH; Lim HI; Lee SK; Kim WW; Kim JS; Kim JH; Choe JH; Yang JH; Nam SJ; Lee JE
    Phytomedicine; 2009 Jun; 16(6-7):573-80. PubMed ID: 19181503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGCG inhibits transforming growth factor-β-mediated epithelial-to-mesenchymal transition via the inhibition of Smad2 and Erk1/2 signaling pathways in nonsmall cell lung cancer cells.
    Liu LC; Tsao TC; Hsu SR; Wang HC; Tsai TC; Kao JY; Way TD
    J Agric Food Chem; 2012 Oct; 60(39):9863-73. PubMed ID: 22957988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer chemoprevention by silibinin: bench to bedside.
    Singh RP; Agarwal R
    Mol Carcinog; 2006 Jun; 45(6):436-42. PubMed ID: 16637061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.
    Gonzalez-Moreno O; Lecanda J; Green JE; Segura V; Catena R; Serrano D; Calvo A
    Exp Cell Res; 2010 Feb; 316(4):554-67. PubMed ID: 20006606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.
    Singh RP; Agarwal R
    Mutat Res; 2004 Nov; 555(1-2):21-32. PubMed ID: 15476849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
    Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
    J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.
    Zi X; Zhang J; Agarwal R; Pollak M
    Cancer Res; 2000 Oct; 60(20):5617-20. PubMed ID: 11059749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.